Amgen Rebuilt R&D Platform To Focus On Speed And Access
Genetics, AI And Other Tools Assembled Over Past Decade
Executive Summary
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
You may also be interested in...
Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains
Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.
Pfizer Executive On Paxlovid’s Development And Design Journey
Senior Pfizer executive outlines the accelerated development approach for Paxlovid, one that took just 17 months, but was done without cutting any corners for safety and also sought to guard against resistance from the design perspective.
Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.